NovaMed to distribute six oncology products for Pfizer China
NovaMed Pharmaceuticals announced June 13 that is has entered into an agreement with Pfizer China under which it will act as the exclusive distributor and promoter for six of Pfizer China's anticancer products. NovaMed expects hospital coverage of the products, Adriamycin, Daunoblastina, Leucovorin, Methotrexate, Estracyt and Farlutal, to increase by 30% to 40% in China.
NovaMed is a specialty pharmaceutical company providing commercialization and outsourcing services in China for global pharmaceutical and biotech companies. The company seeks to license products that have been launched in international markets but are not yet available in China as well as development stage products. NovaMed has successfully in-licensed programs from several multinational pharmaceutical companies, including recent agreements with Sanofi-Aventis, Baxter International, and Meda AB.